Testing for Mycoplasma genitalium and Using Doxycycline as First-Line Therapy at Initial Presentations for Non-Gonococcal Urethritis (NGU) Correlate With Reductions in Persistent NGU

Kelly A Johnson; Madeline Sankaran; Robert P Kohn; Oliver Bacon; Stephanie E Cohen

doi:10.1093/cid/ciac977

Testing for Mycoplasma genitalium and Using Doxycycline as First-Line Therapy at Initial Presentations for Non-Gonococcal Urethritis (NGU) Correlate With Reductions in Persistent NGU

Clin Infect Dis. 2023 May 3;76(9):1674-1677. doi: 10.1093/cid/ciac977.

Authors

Kelly A Johnson¹, Madeline Sankaran², Robert P Kohn², Oliver Bacon^{1

2}, Stephanie E Cohen^{1

2}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
² Population Health Division, San Francisco Department of Public Health, San Francisco, California, USA.

PMID: 36575605
DOI: 10.1093/cid/ciac977

Abstract

We found that the odds of return clinic visits for persistent non-gonococcal urethritis (NGU) were significantly lower (odds ratio: .4; 95% confidence interval: .3-.6; P < .0001) after implementing (1) testing for Mycoplasma genitalium during initial evaluations for NGU and (2) switching from azithromycin to doxycycline as first-line NGU treatment.

Keywords: Mycoplasma genitalium; azithromycin; doxycycline; non-gonococcal urethritis (NGU); persistent non-gonococcal urethritis.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Azithromycin / therapeutic use
Doxycycline / therapeutic use
Humans
Mycoplasma Infections* / diagnosis
Mycoplasma Infections* / drug therapy
Mycoplasma genitalium*
Urethritis* / diagnosis
Urethritis* / drug therapy

Substances

Doxycycline
Azithromycin
Anti-Bacterial Agents